tradingkey.logo

Trevi Therapeutics slips on $100 mln stock sale plans

ReutersJun 2, 2025 8:21 PM

Shares of Trevi Therapeutics TRVI.O down 3.6% in extended trading to $6.09 as co plans equity raise

New Haven, Connecticut-based firm commences $100 mln stock offering

Morgan Stanley. Leerink, Stifel and Cantor are jt bookrunners

Before the bell on Mon, co announced positive topline results from Phase II trial of its therapy, Haduvio, for patients with a type of chronic cough, and said plans Phase III initiation in 2026

With ~101.7 mln shares outstanding, co has about $680 market cap, per LSEG data

TRVI closed down 3% at $6.32 on Mon, trimming YTD gain to 53%

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI